Diagnostic value of dynamic contrast-enhanced magnetic resonance imaging combined with diffusion-weighted imaging in benign and malignant prostate lesions(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2026年第3期
- Page:
- 300-307
- Research Field:
- 医学影像物理
- Publishing date:
Info
- Title:
- Diagnostic value of dynamic contrast-enhanced magnetic resonance imaging combined with diffusion-weighted imaging in benign and malignant prostate lesions
- Author(s):
- ZHOU Yafen1; ZHAO Yini2; QIU Wei1; LOU Yanting3
- 1. Department of Radiology, Chaohu Hospital Affiliated to Anhui Medical University, Chaohu 238000, China 2. Magnetic Resonance Room, Chaohu Hospital Affiliated to Anhui Medical University, Chaohu 238000, China 3. Department of Urology, Chaohu Hospital Affiliated to Anhui Medical University, Chaohu 238000, China
- Keywords:
- Keywords: magnetic resonance imaging enhanced imaging high resolution diffusion-weighted imaging prostate cancer
- PACS:
- R816.7
- DOI:
- DOI:10.3969/j.issn.1005-202X.2026.03.004
- Abstract:
- Abstract: Objective To analyze the application value of high-resolution dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) combined with diffusion-weighted imaging (DWI) in the diagnosis of benign and malignant prostate lesions. Methods A retrospective analysis was conducted on the clinical data of 82 patients with prostate lesions who were admitted to Chaohu Hospital Affiliated to Anhui Medical University from January 2022 to November 2024. All patients underwent DCE-MRI and DWI before pathological examination. Taking pathological results as the gold standard, the differences in DCE-MRI and DWI imaging characteristics, apparent diffusion coefficient (ADC) values, and signal intensity-time (SI-T) curve types were compared between patients with benign and malignant lesions. Additionally, the diagnostic performance of DCE-MRI and DWI, alone and in combination, for differentiating benign and malignant prostate lesions was evaluated. Results Pathological findings revealed that among the 82 patients with prostate lesions, 31 (37.80%) had malignant lesions and 51 (62.20%) had benign lesions. Compared with patients with benign lesions, those with malignant lesions exhibited a lower ADC value on DWI, a higher proportion of type III on the SI-T curve type of DCE-MRI, and a higher frequency of lesions located in the peripheral area (P<0.05). ROC curve analysis demonstrated that the area under the curve (AUC) of DWI-derived ADC value for diagnosing benign and malignant prostate lesions was 0.906 (95% CI: 0.841-0.971). At an ADC value of 14.73×10-4 mm2/s, the sensitivity, specificity and Youden index were 84.30%, 83.90% and 0.682, respectively. DWI and DCE-MRI, both alone and in combination, exhibited favorable consistency with the pathological diagnosis of benign and malignant prostate lesions, with the combined modality showing a higher consistency with pathological results (Kappa value=0.632, 0.677, 0.898, respectively). Compared with DWI and DCE-MRI alone, the combined modality achieved higher accuracy, sensitivity and negative predictive value for the diagnosis of benign and malignant prostate lesions (P<0.05). Logistic regression model was established to predict the malignancy of prostatic lesions using ADC values and SI-T curve types: Logit(P)=-35.716-0.576×ADC value+2.135×SI-T curve type. ROC curve analysis showed that the regression model constructed with ADC value and SI-T curve type had an AUC of 0.967 (95% CI: 0.927-1.000) for differentiating benign from malignant prostatic lesions, with a specificity, sensitivity, and Youden index of 0.980, 0.871, and 0.851, respectively. Conclusion This single-center retrospective study demonstrates that the combination of DWI-derived ADC values and DCE-MRI-derived SI-T curve types enhances the diagnostic performance of differentiating benign from malignant prostatic lesions, with improved diagnostic accuracy, sensitivity, and negative predictive value. However, these findings are based on single-center retrospective data and require further validation through prospective, large-sample researches to strengthen their clinical applicability.
Last Update: 2026-03-27